Evidence map›Paper›PMID 34940995›Full record

ArticleImmunology and cell biology2022

Differential antigenic requirements by diverse MR1-restricted T cells.

Rebecca Seneviratna, Samuel J Redmond, Hamish Eg McWilliam, Rangsima Reantragoon, Jose A Villadangos, James McCluskey, Dale I Godfrey, Nicholas A Gherardin

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Immunology and cell biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rebecca SeneviratnaDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
Samuel J RedmondDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
Hamish Eg McWilliamDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
Rangsima ReantragoonDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
Jose A VilladangosDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
James McCluskeyDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
Dale I GodfreyDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.
Nicholas A GherardinDepartment of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, 3000, Australia.ORCID 0000-0003-4690-2571
Australian Research Council · AUThe University of Melbourne · AU

Funding

Investigating the basis of MAIT cell antigen potencyR01AI148407 · NIAID · UNIVERSITY OF MELBOURNE · PI MCCLUSKEY, JAMES · 2020 to 2024
$2.7M
NIAID NIH HHS R01 AI148407
6 · The paper itself

Abstract

MHC-related protein 1 (MR1) presents microbial riboflavin metabolites to mucosal-associated invariant T (MAIT) cells for surveillance of microbial presence. MAIT cells express a semi-invariant T-cell receptor (TCR), which recognizes MR1-antigen complexes in a pattern-recognition-like manner. Recently, diverse populations of MR1-restricted T cells have been described that exhibit broad recognition of tumor cells and appear to recognize MR1 in association with tumor-derived self-antigens, though the identity of these antigens remains unclear. Here, we have used TCR gene transfer and engineered MR1-expressing antigen-presenting cells to probe the MR1 restriction and antigen reactivity of a range of MR1-restricted TCRs, including model tumor-reactive TCRs. We confirm MR1 reactivity by these TCRs, show differential dependence on lysine at position 43 of MR1 (K43) and demonstrate competitive inhibition by the MR1 ligand 6-formylpterin. TCR-expressing reporter lines, however, failed to recapitulate the robust tumor specificity previously reported, suggesting an importance of accessory molecules for MR1-dependent tumor reactivity. Finally, MR1-mutant cell lines showed that distinct residues on the α1/α2 helices were required for TCR binding by different MR1-restricted T cells and suggested central but distinct docking modes by the broad family of MR1-restricted αβ TCRs. Collectively, these data are consistent with recognition of distinct antigens by diverse MR1-restricted T cells.

Indexed as

Mucosal-Associated Invariant T CellsReceptors, Antigen, T-Cell, alpha-betaHistocompatibility Antigens Class IMinor Histocompatibility AntigensReceptors, Antigen, T-CellHistocompatibility Antigens Class IMinor Histocompatibility AntigensReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-betaAntigen processing and presentationMAITMR1T-cell receptor

Identifiers

PMID34940995
PMCPMC9033883
OpenAlexW4200198128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.